At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 312 enrolled
Drug / intervention
Influenza A (H5N1) Virus Monovalent Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial to Evaluate the Immunogenicity of Accelerated Primary Vaccination With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64
In Brief
A Phase 2 clinical trial evaluating Influenza A (H5N1) Virus Monovalent Vaccine for Influenza. Completed, enrolled 312 participants across 3 sites.
Detailed Summary
The purpose of the study is to characterize the immunogenicity \& safety of 2 doses of GSK's avian flu vaccine GSK 1557484A given according to different regimens to adults aged 18 to 64 years
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2008
Primary CompletionAug 2008
Study CompletionJan 2009
TodayJul 2026
First PostedJun 12, 2008
Enrollment StartJun 5, 2008
Primary CompletionAug 13, 2008
Study CompletionJan 8, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.1 years ago
Interventions
Influenza A (H5N1) Virus Monovalent Vaccinebiological
Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.